Our mission
A decisive step forward in immunotherapy
Our Approach
A comprehensive outlook
Our team is dedicated to advancing CAR-T cell research through innovative methods. Using a unique version of the Sleeping Beauty transposase, we have improved the biochemical properties and can directly modify the genome. Additionally, we are developing strategies to manage therapy side effects and exploring new targets. We are excited to participate in clinical trials like CARAMBA and collaborate with international partners to improve accessibility and speed up the development and the clinical translation of CAR-T therapy in Europe.
See our latest publications
Follow the work of our researchers
Publications
- Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. Ammar D, Sanges C, Henderson D et al. Cytotherapy. 2025 Sep 23:101984. doi: 10.1016/j.jcyt.2025.09.007. Epub ahead of print. PMID: 41217312.
Go to publication - Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma. Riester Z et al. Mol Ther. 2025 Oct 24:S1525-0016(25)00867-6. doi: 10.1016/j.ymthe.2025.10.046. Epub ahead of print. PMID: 41137393.
Go to publication - LMP2A-Targeting CAR-T Cells Equipped With Inducible IL-18 to Address EBV-Associated Malignancies. Dragon AC, Thoelke S, Mausberg P, Zimmermann K, Blasczyk R, Hudecek M, Abken H, Schambach A, Maecker-Kolhoff B, Eiz-Vesper B. HLA. 2025 Oct;106(4):e70439. doi: 10.1111/tan.70439. PMID: 41116979; PMCID: PMC12538270.
Go to publication - Fine tuning towards the next generation of engineered T cells, Nguyen TT, et al. Nat Biomed Eng. 2025 Oct 10. doi: 10.1038/s41551-025-01492-8,
Go to publication - ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice, Weber J, et al. Cell Rep Med. 2025 Oct 6:102400. doi: 10.1016/j.xcrm.2025.102400
Go to publication - Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testing, Michael Hudecek, Nature. 2025 Sep 24. doi: 10.1038/d41586-025-02595-7
Go to publication - Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe, Elise Ra Pennings, et al. Blood Adv. 2025 Sep 24:bloodadvances.2025017081. doi: 10.1182/bloodadvances.2025017081.
Go to publication - Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities, Petri K, et al. Nat Rev Clin Oncol. 2025 Sep 19. doi: 10.1038/s41571-025-01072-4.
Go to publication - Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma, Neubert S, et al. Leukemia. 2025 Oct;39(10):2563-2567. doi: 10.1038/s41375-025-02757-6.
Go to publication - Impact of Serum/Xeno-Free Medium and Cytokine Supplementation on CAR-T Cell Therapy Manufacturing in Stirred Tank Bioreactors, Couto P S. et al. Biotechnol J. 2025 Sep;20(9):e70114. doi: 10.1002/biot.70114.
Go to publication - Direct visualization of chimeric antigen receptors on primary human T cells using d STORM super-resolution microscopy, Gehrke L, et al.Front Immunol. 2025 Aug 1:16:1632823. doi: 10.3389/fimmu.2025.1632823. eCollection 2025.
Go to publication - Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies, Weirauch U, et al. NPJ Digit Med. 2025 Aug 1;8(1):493. doi: 10.1038/s41746-025-01809-6.
Go to publication - Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens, Rieger L, et al. Blood. 2025 Jul 10:blood.2024027616. doi: 10.1182/blood.2024027616. Online ahead of print.
Go to publication - Virtual twins for personalised CAR T-cell therapy in myeloma, Reiche K, et al. , Lancet Haematol. 2025 Jul;12(7):e490-e491. doi: 10.1016/S23523026(25)00170-X.
Go to publication - Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases, Elmar Jaeckel, Scott L Friedman, Michael Hudecek, Ulrike Protzer, J Hepatol. 2025 Jun 20:S0168-8278(25)02274-3. doi: 10.1016/j.jhep.2025.06.007
Go to publication - European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring, De Angelis B, et al. Front Immunol. 2025 Apr 24:16:1567582. doi: 10.3389/fimmu.2025.1567582. eCollection 2025.
Go to publication - Tailoring CAR surface density and dynamics to improve CAR-T cell therapy, Hinckley-Boned A, et al. J Immunother Cancer. 2025 Apr 29;13(4):e010702. doi: 10.1136/jitc-2024-010702.
Go to publication - Short-Chain Fatty Acids Modulate Anti-ROR1 CAR T-Cell Function and Exhaustion in an Intestinal Adenocarcinoma-on-Chip Model, Wegner V C, et al. Adv Healthc Mater. 2025 May;14(13):e2405003. doi: 10.1002/adhm.202405003. Epub 2025 Apr 18.
Go to publication - Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies, Peter J, et al. Oncol Res Treat. 2025;48(5):265-279. doi: 10.1159/000543806. Epub 2025 Mar 14.
Go to publication - Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells, Staudt S et al., doi: https://doi.org/10.1101/2024.08.19.608538, February 4, 2025.
Go to publication - Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection, Dragon A C, et al. Mol Ther. 2025 Mar 5;33(3):1031-1047. doi: 10.1016/j.ymthe.2025.01.009. Epub 2025 Jan 11.
Go to publication - A data management system for precision medicine, Jacobs J J L, et al. PLOS Digit Health. 2025 Jan 9;4(1):e0000464. doi: 10.1371/journal.pdig.0000464. eCollection 2025 Jan.
Go to publication - Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors, Mestermann K, et al. BioDrugs. 2025 Jan;39(1):33-51. doi: 10.1007/s40259-024-00688-9. Epub 2024 Nov 26. Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors | BioDrugs.
Go to publication
See our latest publications
Follow the work of our researchers
Publications
- Luu, M, Visekruna, A (2022). Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis. Sig Transduct Target Ther 7, 360.
Go to publication - Lock D, Monjezi R, Brandes C, et al (2022). Automated, scaled, transposon-based production of CAR T cells. Journal for ImmunoTherapy of Cancer;10.
Go to publication - Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I (2022). Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside? J Immunother Cancer. May;10(5).
Go to publication - Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M (2022). Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. May;10(5).
Go to publication - Brosinsky P, Leister H, Cheng N, Varelas X, Visekruna A, Luu M (2022). Verteporfin protects against Th17 cell-mediated EAE independent of YAP inhibition. Eur J Immunol.
Go to publication
- Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I (2021)Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia.Cancers; 13(24):6157.
Go to publication - Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M et al. (2021)
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol; S0923-7534(21)04876-6.
Go to publication - Luu, M, Visekruna, A (2021) Microbial metabolites: novel therapeutic tools for boosting cancer therapies. Trends in Cell Biology, Volume 31, Issue 11.
Go to publication - Jetani, H, Navarro-Bailón, A, Maucheret, M et al. (2021) Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML). Blood 2021.
Go to publication - Luu, M, Riester, Z, Baldrich, A et al. (2021) Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat Commun 12, 4077.
Go to publication - Prommersberger, S, Reiser, M, Beckmann, J et al. (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther 28, 560–571. Go to publication - Da Vià, M.C., Dietrich, O., Truger, M. et al. (2021)
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma.Nat Med 27, 616–619.
Go to Publication
- Prommersberger S, Hudecek M, Nerreter T. (2020) Antibody-Based CAR T Cells Produced by Lentiviral Transduction.
Curr Protoc Immunol. Mar;128(1):e93.
Go to publication
